AGP Executive Report
Last update: 8 hours agoPediatric Cancer Trial Access: A Boston-area study finds clinicians may “gatekeep” by holding back trial offers from Black and Hispanic families facing hardship, even when trust is high—highlighting a fixable enrollment barrier. Cancer Prevention Research: Scientists are testing vaccines aimed at intercepting Lynch syndrome–linked colorectal cancer before it becomes full-blown tumors, with early results building momentum for larger trials. FDA & Devices: BlueWind Medical won FDA clearance for Revi Extend, a next-gen implantable therapy for urge urinary incontinence designed to last up to 15 years. Immunotherapy Breakthrough: Rice researchers report a localized IL-10 “halo” approach that helps implanted pancreatic beta cells survive longer in diabetic mice, pointing toward better cell-therapy outcomes. Massachusetts Health Policy: Gov. Healey signed sweeping anti–ICE access protections covering courts, schools, and hospitals, reshaping how health care facilities handle immigration enforcement. Clinical Capacity & AI: Assort Health named a first Chief Medical Officer to help health systems use AI agents to reduce admin friction and improve patient access.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
